129 related articles for article (PubMed ID: 38366886)
1. Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study.
Wei Q; Xu X; Li J; Wang C; Chen W; Xie Y; Luo C; Chen L; Chu J; Wu W; Han Z; Yang Y; Hu Z; Xu Q; Ying J
Oncologist; 2024 Apr; 29(4):364-e578. PubMed ID: 38366886
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study.
Yan Y; Li H; Wu S; Wang G; Luo H; Niu J; Cao L; Hu X; Xu H; Jia W; Sun Y; Yao Y; Chen W; Ke L; Hu B; Ji C; Sun Y; Chen J; Li M; He Y
Ann Transl Med; 2022 Feb; 10(4):205. PubMed ID: 35280426
[TBL] [Abstract][Full Text] [Related]
5. PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study.
Wei Q; Yuan X; Li J; Xu Q; Ying J
Transl Cancer Res; 2020 Sep; 9(9):5315-5322. PubMed ID: 35117897
[TBL] [Abstract][Full Text] [Related]
6. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
Wang Y; Gong J; Wang A; Wei J; Peng Z; Wang X; Zhou J; Qi C; Liu D; Li J; Lu M; Lu Z; Cao Y; Yuan J; Zhang R; Fang J; Zhang X; Shen L
EClinicalMedicine; 2024 Feb; 68():102415. PubMed ID: 38235421
[TBL] [Abstract][Full Text] [Related]
7. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Jing C; Wang J; Zhu M; Bai Z; Zhao B; Zhang J; Yin J; Yang X; Liu Z; Zhang Z; Deng W
Cancer Immunol Immunother; 2022 Nov; 71(11):2597-2608. PubMed ID: 35304622
[TBL] [Abstract][Full Text] [Related]
8. Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.
Zhang L; Wang W; Ge S; Li H; Bai M; Duan J; Yang Y; Ning T; Liu R; Wang X; Ji Z; Wang F; Zhang H; Ba Y; Deng T
BMC Cancer; 2023 Mar; 23(1):211. PubMed ID: 36872337
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
Xu J; Zhang Y; Jia R; Yue C; Chang L; Liu R; Zhang G; Zhao C; Zhang Y; Chen C; Wang Y; Yi X; Hu Z; Zou J; Wang Q
Clin Cancer Res; 2019 Jan; 25(2):515-523. PubMed ID: 30348638
[TBL] [Abstract][Full Text] [Related]
10. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
12. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of neoadjuvant chemoradiotherapy plus apatinib for patients with locally advanced, HER2-negative, Siewert's type II-III adenocarcinoma of esophagogastric junction: a single-arm, open-label, phase II trial.
Guo H; Li Y; Lin C; Cheng Y; Zhang Z; Wang D; Zhao X; Liu Y; Jing S; Yang P; Tian Y; Liu Y; Wang J; Zhao Q
Am J Transl Res; 2021; 13(8):9015-9023. PubMed ID: 34540013
[TBL] [Abstract][Full Text] [Related]
14. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
15. Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma.
Jiang M; Zhang C; Hu Y; Li T; Yang G; Wang G; Zhu J; Shao C; Hou H; Zhou N; Liu K; Zhang X
Oncologist; 2022 Nov; 27(11):e856-e869. PubMed ID: 35857405
[TBL] [Abstract][Full Text] [Related]
16. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study.
Yanwei L; Feng H; Ren P; Yue J; Zhang W; Tang P; Shang X; Pang Q; Liu D; Chen C; Pan Z; Tao YZ
Oncologist; 2020 Oct; 25(10):e1464-e1472. PubMed ID: 32342599
[TBL] [Abstract][Full Text] [Related]
18. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
Bang YJ; Ruiz EY; Van Cutsem E; Lee KW; Wyrwicz L; Schenker M; Alsina M; Ryu MH; Chung HC; Evesque L; Al-Batran SE; Park SH; Lichinitser M; Boku N; Moehler MH; Hong J; Xiong H; Hallwachs R; Conti I; Taieb J
Ann Oncol; 2018 Oct; 29(10):2052-2060. PubMed ID: 30052729
[TBL] [Abstract][Full Text] [Related]
19. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
Song Y; Li N; Li Q; Liang X; Zhang S; Fan Q; Yin X; Zhuang Z; Liu Y; Zhang J; Kou X; Zhong H; Wang X; Dou Y; Huang J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060149
[TBL] [Abstract][Full Text] [Related]
20. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Lan C; Shen J; Wang Y; Li J; Liu Z; He M; Cao X; Ling J; Huang J; Zheng M; Zou G; Yan H; Liu Q; Yang F; Wei W; Deng Y; Xiong Y; Huang X
J Clin Oncol; 2020 Dec; 38(34):4095-4106. PubMed ID: 33052760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
